| Literature DB >> 35515565 |
Xiu-Hong Wu1, Xiao-Lan Sun1, Chuang Zhao1, Jin-Qi Zhang1, Xu Wang1, Ai-Hua Zhang1, Xi-Jun Wang1,2,3.
Abstract
This study was employed to explore the potential biomarkers of endometriosis of cold coagulation and blood stasis (ECB) model rats and the effective mechanism of action of paeoniflorin (PF). The serum metabolomics approach was carried out using the UPLC-MS technique with a pattern recognition approach to prove the possible biomarkers of the ECB model rats and the perturbed pathways. Subsequently, the mechanism of PF treatment of this disease model was elucidated. The results revealed that the serum metabolism profiles in two groups were also separated significantly. Moreover, 8 biomarkers were found in the positive mode, and 5 biomarkers were found in the negative mode. Totally, 13 biomarkers participated in the metabolism of phenylalanine, arachidonic acid, etc. After treatment with PF, 10 biomarkers were regulated. Among the 10 biomarkers, 4 were statistically significant: l-phenylalanine, l-tryptophan, LysoPC (18:4(6Z,9Z,12Z,15Z)), and LysoPC (16:1(9Z)). We initially confirmed that PF could significantly regulate the metabolic expression of multiple metabolic pathways in the ECB model rats. For the first time, this study explored the mechanism of action of PF treatment based on the metabolic pathways of the organism and demonstrated the potential of the metabolomics techniques for the study of drug action mechanisms. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35515565 PMCID: PMC9065745 DOI: 10.1039/c9ra03525g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Changes in endometrium graft volume.
Fig. 2Endometriosis effect of shape and structure of ectopic endometrial cells in the different groups after oral administration of PF for 28 days (100× magnification). Con.: control group; Mod.: model group; GY4.: PF group.
Effect of endometrium grafts volume in serum of GFW (X̄ ± SD)a
| Group | Rats/ | Ectopic tissue volume/mm3 |
|---|---|---|
| Control group 1 | 10 | 0.00 ± 0.00 |
| Model group 1 | 8 | 87.85 ± 5.09ΔΔ |
| Control group 2 | 10 | 0.00 ± 0.00 |
| Model group 2 | 9 | 92.87 ± 8.54 |
| PF group | 9 | 80.07 ± 7.12** |
Data are expressed as means ± SD. Compared with normal control group 1, ΔP < 0.05; compared with model group 2, *P < 0.05, **P < 0.01.
Fig. 3UPLC-MS base peaks ion (BPI) intensity chromatograms of ECB model rats in control group (A) and model group (B) by positive and negative ion modes.
Fig. 4Score plot of serum profile of sham group and model group scanned by positive and negative ion modes. (Data were analyzed by PCA.) Note: A: In the positive ion mode, B: in the negative ion mode; Con: the sham group, Mod: the model group.
Fig. 5Score plot of serum profile of sham group and model group scanned by positive and negative ion modes. (Data were analyzed by OPLS-DA.) Note: A: in the positive ion mode, B: in the negative ion mode; Con: the sham group, Mod: the model group.
Serum potential biomarkers related to ECB identified in positive and negative ion modea
| No. |
| Determined mass | Calc mass | Actual mass | [M − H]−/[M + H]+ | mDa | ppm | Proposed composition | Postulated identity | HMDB number | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1.36 | 166.0869 | 166.0868 | 165.0789 | [M + H]+ | 0.1 | 0.6 | C9H11NO2 |
| HMDB00159 | ↑ΔΔ |
| 2 | 1.73 | 203.0827 | 203.0821 | 204.0898 | [M − H]- | 0.6 | 3 | C11H12N2O2 |
| HMDB00929 | ↓Δ |
| 3 | 2.20 | 178.0504 | 178.0504 | 179.0582 | [M − H]− | 0 | 0 | C9H9NO3 | Hippuric acid | HMDB00714 | ↑ΔΔ |
| 4 | 4.79 | 514.293 | 514.2934 | 515.3011 | [M − H]− | −0.4 | −1 | C26H46NO7P | LysoPC (18:4(6 | HMDB10389 | ↓ΔΔ |
| 5 | 5.51 | 373.2745 | 373.2473 | 372.2664 | [M + H]+ | 0.2 | 0.5 | C24H36O3 | Cervonoyl ethanolamide | HMDB13627 | ↓ΔΔ |
| 6 | 7.25 | 494.3242 | 494.3247 | 493.3168 | [M + H]+ | −0.5 | −1 | C24H48NO7P | LysoPC (16:1(9 | HMDB10383 | ↓ΔΔ |
| 7 | 7.54 | 520.34 | 520.3403 | 519.3324 | [M + H]+ | −0.3 | −0.6 | C26H50NO7P | LysoPC (18:2(9 | HMDB10386 | ↓Δ |
| 8 | 7.71 | 500.279 | 500.2777 | 501.2855 | [M − H]− | 1.2 | 2.4 | C25H44NO7P | LysoPE (0:0/20:4 (8 | HMDB11488 | ↓ΔΔ |
| 9 | 8.13 | 454.2939 | 454.2934 | 453.2855 | [M + H]+ | 0.5 | 1.1 | C21H44NO7P | LysoPE (16:0/0:0) | HMDB11503 | ↓ΔΔ |
| 10 | 8.23 | 496.3404 | 496.3403 | 495.3324 | [M + H]+ | 0.1 | 0.2 | C24H50NO7P | LysoPC (16:0) | HMDB10382 | ↓ΔΔ |
| 11 | 8.64 | 522.3563 | 522.356 | 521.3481 | [M + H]+ | 0.3 | 0.6 | C26H52NO7P | LysoPC (18:1(9 | HMDB02815 | ↓Δ |
| 12 | 8.99 | 319.2278 | 319.2273 | 320.2351 | [M − H]− | 0.5 | 1.6 | C20H32O3 | 5-HETE | HMDB11134 | ↑ΔΔ |
| 13 | 9.61 | 482.0325 | 482.3247 | 481.3168 | [M + H]+ | 0.3 | 0.6 | C23H48NO7P | LysoPC (15:0) | HMDB10381 | ↓ΔΔ |
↑↓ indicates that the level of the marker is increased or decreased in the urine of rats in the ECB model group; compared with the control group, ΔP < 0.05, ΔΔP < 0.01.